Published in Can J Infect Dis Med Microbiol on March 23, 2015
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med (2011) 7.13
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med (2014) 5.23
Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med (2014) 4.95
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 4.07
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis (2014) 3.69
Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis (2014) 3.54
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet (2014) 3.21
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis (2014) 2.74
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med (2014) 2.39
Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med (2014) 2.05
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001. Int J Tuberc Lung Dis (2015) 1.53
Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect Dis (2004) 1.43
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr (2014) 1.14
Cost-effectiveness of a tuberculosis active case finding program targeting household and neighborhood contacts in Cambodia. Am J Trop Med Hyg (2014) 1.13
Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis (2014) 1.11
The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PLoS One (2014) 0.99
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. Int J Tuberc Lung Dis (2014) 0.98
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One (2014) 0.86
Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother (2014) 0.85
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol (2014) 0.83
Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One (2014) 0.83
Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. J Gastroenterol Hepatol (2014) 0.80
A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania. BMC Infect Dis (2014) 0.79
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine (2014) 0.79
Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa. PLoS One (2014) 0.77
Reducing communication delays and improving quality of care with a tuberculosis laboratory information system in resource poor environments: a cluster randomized controlled trial. PLoS One (2014) 0.77
Homeopathic treatment in addition to standard care in multi drug resistant pulmonary tuberculosis: a randomized, double blind, placebo controlled clinical trial. Homeopathy (2014) 0.77
The Effect of Garcin® in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients. Iran J Pharm Res (2014) 0.76
Outpatient parenteral antimicrobial therapy. Can J Infect Dis Med Microbiol (2013) 0.92
Ebola virus disease. Can J Infect Dis Med Microbiol (2014) 0.84
The dollars and sense of chronic hepatitis C infection management. Can J Infect Dis Med Microbiol (2015) 0.75
Bill C-442: Shining the limelight on the Lyme-like? Can J Infect Dis Med Microbiol (2014) 0.75
The changing culture of the microbiology laboratory. Can J Infect Dis Med Microbiol (2013) 0.75
Management of severe infections: A time to keep a cool head or a hot topic for clinical trials? Can J Infect Dis Med Microbiol (2014) 0.75